SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Multiple Sclerosis
This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Coyle, P
Right arrow Articles by Lublin, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coyle, P
Right arrow Articles by Lublin, F
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Multiple Sclerosis
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

research-article

Optimizing Outcomes in Multiple Sclerosis – A Consensus Initiative

P Coyle

Dept. of Neurology, Stony Brook University Medical Center, HSC T12–020, Stony Brook, NY, 11794–8121

B Arnason

Dept. of Neurology, Stony Brook University Medical Center, HSC T12–020, Stony Brook, NY, 11794–8121

B Hurwitz

Dept. of Neurology, Stony Brook University Medical Center, HSC T12–020, Stony Brook, NY, 11794–8121

F Lublin

Dept. of Neurology, Stony Brook University Medical Center, HSC T12–020, Stony Brook, NY, 11794–8121

Background

Initiation of immunomodulators in patients experiencing a clinically isolated syndrome (CIS) may delay progression to clinically definite MS. However, lack of consensus remains on many issues affecting optimal management of MS.

Method

A panel of 21 MS experts met during 9 meetings to explore key issues in MS and CIS. Meetings addressed 3 phases: 1. CIS definition and diagnosis; 2. initial therapy; and 3. monitoring disease progression and treatment efficacy. Newsletters covering each phase were sent to 5000 U.S.-based neurologists who were invited to participate in an online survey on key issues.

Results

Most panel members agreed that early treatment may minimize neurodegeneration and most would recommend it for patients; that a dose-response relationship exists for beta-interferon therapy; that more aggressive therapy was most effective early in the disease course; and, that MRI has a role in monitoring disease progression. In face of suboptimal response, most would switch patients to a different therapy; while combination therapy would be reserved for those failing monotherapy regimes. Most online survey respondents agreed with these positions.

Conclusions

There was uniform consensus from this panel of MS experts that early initiation of immunomodulator therapy was beneficial for CIS patients.

Key Words: clinically isolated syndrome • copolymer 1 • interferon beta 1a • interferon beta 1b • McDonald Criteria • mitoxantrone • multiple sclerosis • natalizumab

References

  • http://www.nationalmssociety.org
  • 2 PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group . Lancet 1998; 359: 1498 – 1504 .
  • 3 Jacobs LD Beck RW Simon JH Kinkel RP Brownscheidle CM Murray TJ . Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group . N Engl J Med 2000; 343: 898 – 904 .[Abstract/Free Full Text]
  • 4 Comi G Filippi M Barkhof F Durelli L Edan G Fernandez O . Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomized study . Lancet 2001; 357: 1576 – 1582 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 5 Kappos L Polman CH Freedman MS Edan G Hartung HP Miller DH . Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes . Neurology 2006; 67: 1242 – 1249 .[Abstract/Free Full Text]
  • 6 Kappos L Freedman MS Polman CH Edan G Hartung HP Miller DH . Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study . Lancet 2007; 370: 389 – 397 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 7 Goodin DS Frohman EM Garmany GP Halper J Likosky WH Lublin FD . Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines . Neurology 2002; 58: 169 – 178 .[Free Full Text]
  • 8 Frohman EM Goodin DS Calabresi PA Corboy JR Coyle PK Filippi M . The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology . Neurology 2003; 61: 602 – 611 .[Abstract/Free Full Text]
  • 9 Miller D Barkhof F Montalban X Thompson A Filippi M . Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis . Lancet Neurol 2005; 4: 281 – 288 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 10 Brex PA Ciccarelli O O’Riordan JI Sailer M Thompson J Miller DH . A longitudinal study of abnormalities on MRI and disability from multiple sclerosis . N Engl J Med 2002; 346: 158 – 164 .[Abstract/Free Full Text]
  • 11 O’Riordan JI Thompson AJ Kingsley DP MacManus DG Kendall BE Rudge P . The prognostic value of brain MRI in clinically isolated syndromes of the CNS. A 10-year follow-up . Brain 1998; 121: 495 – 503 .[Abstract/Free Full Text]
  • 12 Lovrecic L Ristic S Starcevic-Cizmarevic N Jazbec SS Sepcic J Kapovic M . Angiotensin-converting enzyme I/D gene polymorphism and risk of multiple sclerosis . Acta Neurol Scand 2006; 114: 374 – 377 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 13 Avasarala JR Cross AH Trotter JL . Oligoclonal band number as a marker for prognosis in multiple sclerosis . Arch Neurol 2001; 58: 2044 – 2045 .[Abstract/Free Full Text]
  • http://www.emedicine.com/radio/topic488htm
  • 15 Lee AG Lin DJ Kaufman M Golnik KC Vaphiades MS Eggenberger E . Atypical features prompting neuroimaging in acute optic neuropathy in adults . Can J Ohthalmol 2000; 35: 325 – 330 .
  • 16 Graber DJ Levy M Kerr D Wade WF . Neuromyelitis optica pathogenesis and aquaporin 4 . J Neuroinflammation 2008; 5: 22 .[CrossRef][Medline] [Order article via Infotrieve]
  • http://www.webcare.md/ArticleDisplay720c2216.aspx
  • 18 Matiello M Jacob A Wingerchuk DM Weinshenker BG . Neuromyelitis optica . Curr Opin Neurol 2007; 20: 255 – 260 .[Web of Science][Medline] [Order article via Infotrieve]
  • 19 Lennon VA Kryzer TJ Pittock SJ Verkman AS Hinson SR . IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel . J Exp Med 2005; 202: 473 – 477 .[Abstract/Free Full Text]
  • 20 Wingerchuk DM Lucchinetti CF . Comparative immunopathogenesis of acute disseminated encephalomyelitis, neuromyelitis optica, and multiple sclerosis . Curr Opin Neurol 2007; 20: 343 – 350 .[Web of Science][Medline] [Order article via Infotrieve]
  • 21 Traboulsee AL Li DK . The role of MRI in the diagnosis of multiple sclerosis . Adv Neurol 2006; 98: 125 – 146 .[Medline] [Order article via Infotrieve]
  • 22 Rocca MA Agosta F Sormani MP Fernando K Tintoré M Korteweg T . A three-year, multi-parametric MRI study in patients at presentation with CIS . J Neurol. 2008; 255: 683 – 691 .[Medline] [Order article via Infotrieve]
  • http://www.medscape.com/viewarticle/566550
  • 24 Rovira A Swanton J Tintoré M Huerga E Barkhof F Filippi M . How early can the diagnosis of multiple sclerosis be ascertained with a single MRI scan? Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 270.
  • 25 Swanton JK Rovira A Tintoré M Altmann D Barkhof F Filippi M . MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study . Lancet Neurol 2007; 6: 677 – 686 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 26 McDonald WI Compston A Edan G Goodkin D Hartung HP Lublin FD . Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis . Ann Neurol 2001; 50: 121 – 127 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 27 Polman CH Reingold SC Edan G Filippi M Hartung HP Kappos L . Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" . Ann Neurol 2005; 58: 840 – 846 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 28 Swanton JK Fernando K Dalton CM Miszkiel KA Thompson AJ Plant GT . Modification of MRI criteria for multiple sclerosis in patients with clinically isolated syndromes . J Neurol Neurosurg Psychiatry 2006; 77: 830 – 833 .[Abstract/Free Full Text]
  • 29 Swanton JK Fernando KT Dalton CM Miszkiel KA Plant GT Thompson AJ . Brain lesion number and spinal cord lesions in clinically isolated syndrome patients and the risk for clinically definite multiple sclerosis. Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 269.
  • 30 Tintoré M Rovira A Río J Nos C Grive E Sastre-Garriga J . New diagnostic criteria for multiple sclerosis: application in first demyelinating episode . Neurology 2003; 60: 27 – 30 .[Abstract/Free Full Text]
  • 31 Freedman MS Polman C Kappos L Edan G Hartung H-P Miller D . Betaseron in Newly Emerging Multiple Sclerosis for Initial Treatment (BENEFIT): Effects of Immediate vs. Early Onset of Interferon Beta-1b Treatment. Programs and abstracts of the American Academy of Neurology 59th Annual Meeting; April 28-May 5, 2007.; Boston, MA. Abstract S02.004.
  • http://www.medscape.com/viewarticle/573185_print
  • 33 Kinkel RP Kollman C O’Connor P Murray TJ Simon J Arnold D . IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event . Neurology 2006; 66: 678 – 684 .[Abstract/Free Full Text]
  • 35 Trojano M Amao MP Avolio C Bergamaschi R Cavalla P Durelli L . The real life impact of early versus delayed treatment of interferon beta on long-term disability progression in relapsing-remitting multiple sclerosis. Presented at the 60th annual meeting of the American Academy of Neurology. Held in Chicago IL, April 13-20, 2008. Poster session.
  • 36 Clerico M;  Faggiano F;  Palace J;  Rice G;  Intore M;  Durelli L;  . Recombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosis. Cochrane Database Syst Rev 2008;Apr 16;(2):CD005278.
  • 37 Bjartmar C Trapp BD . Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences . Curr Opin Neurol 2001; 14: 271 – 278 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 38 Kuhlmann T Lingfeld G Bitsch A Schuchardt J Brück W . Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time . Brain 2002; 125: 2202 – 2212 .[Abstract/Free Full Text]
  • 39 DeStefano N Guidi L Stromillo ML Bartolozzi ML Federico A . Imaging neuronal and axonal degeneration in multiple sclerosis . Neurol Sci 2003; 24(suppl 5): S283 – S286 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 40 Pittock SJ Lucchinetti CF . The pathology of MS: new insights and potential clinical applications . Neurologist 2007; 13: 45 – 56 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 41 Glaser GH Merritt HH . Effects of ACTH and cortisone in multiple sclerosis . Trans Am Neurol Assoc 1951; 56: 130 – 133 .[Medline] [Order article via Infotrieve]
  • 42 MacLean HJ Freedman MS . Immunologic therapy for relapsing-remitting multiple sclerosis . Curr Neurol Neurosci Rep 2001; 1: 277 – 285 .[Medline] [Order article via Infotrieve]
  • 43 Inglese M . Multiple sclerosis: new insights and trends . AJNR Am J Neuroradiol 2006; 27: 954 – 957 .[Free Full Text]
  • 44 Comi G Pulizzi A Rovaris M Abramsky O Arbizu T Boiko A . Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study . Lancet 2008; 371: 2085 – 2092 .[CrossRef][Medline] [Order article via Infotrieve]
  • 45 Cohen JA Rovaris M Goodman AD Ladkani D Wynn D Filippi M . 9006 Study Group. Randomized, double-blind, dose comparison study of glatiramer acetate in relapsing-remitting MS . Neurology 2007; 68: 939 – 944 .[Abstract/Free Full Text]
  • 46 Ruggieri RA Aviolio C Livrea P Trojano M . Glatiramer acetate in multiple sclerosis: a review . CNS Drug Rev 2007; 13: 178 – 191 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 47 Chwastiak LA Ehde DM . Psychiatric issues in multiple sclerosis . Psychiatr Clin North Am 2007; 30: 803 – 817 .[Medline] [Order article via Infotrieve]
  • 48 Río J Porcel J Téllez N Sánchez-Betancourt A Tintoré M Arévalo MJ . Factors related with treatment adherence to interferon beta and glatiramer acetate therapy in multiple sclerosis . Mult Scler 2005; 11: 306 – 309 .[Abstract/Free Full Text]
  • 49 Daugherty KK Butler JS Mattingly M Ryan M . Factors leading patients to discontinue multiple sclerosis therapies . J Am Pharm Assoc 2005; 45: 371 – 375 .[CrossRef]
  • 50 Devonshire V Lapierre Y MacDonell R Ramo Tello C Patti F Fontoura P . A multivariate analysis of the Global Adherence Project to determine key factors associated with adherence to multiple sclerosis disease-modifying therapies. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 169.
  • 51 deSeze J Borgel F Brudon F . Immunomodulator treatments and multiple sclerosis: compliance and factors of adherence to treatment. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 171.
  • 52 Edan G Freedman MS Hartung H-P Kappos L Miller DH Montalbán X . Adherence, tolerability and quality of life: Betaferon® therapy over 3 years in patients with a first event suggestive of multiple sclerosis. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 183.
  • 53 Schwid SR Panitch HS . Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis . Clin Ther 2007; 29: 2031 – 2048 .[Medline] [Order article via Infotrieve]
  • 54 Durelli L Verdun E Barbero P Bergui M Versino E Ghezzi A . Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) . Lancet 2002; 359: 1453 – 1460 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 55 Coyle PK Barkhof F Chang P Jeffery DR Mikol DD Stubinski B . The REGARD trial: safety and immunogenicity from a randomised, assessor-blinded trial of interferon beta-1a and glatiramer acetate in relapsing-remitting multiple sclerosis. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 232B.
  • 56 Mikol DD Barkhof F Chang P Coyle PK Jeffery DR Schwid SR . Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomized, parallel, open-label trial . Lancet Neurol. 2008; (Sep): 10 [Epub ahead of print].
  • http://www.reuters.com/article/pressRelease/idUS48312+07-Jul-2008+BW20080707
  • 58 Durelli L . Dose and frequency of interferon treatment matter—INCOMIN and OPTIMS . J Neurol 2003; 250(Suppl 4): IV9 – IV14 .
  • 59 Judica E Rovaris M Ceccarelli A Ghezzi A Martinelli V Comi G . A three-year diffusion tensor MRI study of grey matter damage progression during the earliest clinical stages of multiple sclerosis. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 635.
  • 60 Chiu A Richert N Ehrmantraut M Ohayon J Cantor F Frank J . Characterisation of response to treatment with interferon beta-1b using contrast-enhancing lesions lesion frequency as a primary outcome measure: a 3-year monthly imaging study. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 637.
  • 61 The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group . Neurology 1993; 43: 655 – 661 .[Abstract/Free Full Text]
  • 62 Rudick RA Goodkin DE Jacobs LD Cookfair DL Herndon RM Richert JR . Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) . Neurology 1997; 49: 358 – 363 .[Abstract/Free Full Text]
  • 63 Durelli L Barbero P Bergui M Versino E Bassano MA Verdun E . MRI activity and neutralizing antibody as predictors of response to interferon beta treatment in multiple sclerosis . J Neurol Neurosurg Psychiatry 2008; 79: 646 – 651 .[Abstract/Free Full Text]
  • 64 Kappos L . Effects of drugs in secondary disease progression in patients with multiple sclerosis . Mult Scler 2004; 10(suppl 1): S46 – S54 .[Abstract/Free Full Text]
  • 65 Fox EJ . Management of worsening multiple sclerosis with mitoxantrone: a review . Clin Ther 2006; 28: 461 – 474 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 66 Cocco E Marchi P Sardu C Russo P Paolillo A Mascia M . Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis . Mult Scler 2007; 13: 975 – 980 .[Abstract/Free Full Text]
  • 67 LePage E Leray E Taurin G Coustans M Chaperon J Morrisey SP . Mitoxantrone as induction treatment in aggressive relapsing remitting multiple sclerosis: treatment response factors in a 5 year follow-up observational study of 100 consecutive patients . J Neurol Neurosurg Psychiatry 2008; 79: 52 – 56 .[Abstract/Free Full Text]
  • 68 Zipoli V Portaccio E Hakiki B Siracusa G Sorbi S Amato MP . Intravenous mitoxantrone and cyclophophamide as second-line therapy in multiple sclerosis: an open-label comparative study of efficacy and safety . J Neurol Sci 2008; 266: 25 – 30 .[CrossRef][Medline] [Order article via Infotrieve]
  • 69 Rovaris M Confavreux C Furlan R Kappos L Comi G Filippi M . Secondary progressive multiple sclerosis: current knowledge and future challenges . Lancet Neurol. 2006; 5: 343 – 354 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 70 Brown MG Kirby S Skedgel C Fisk JD Murray TJ Bhan V . How effective are disease-modifying drugs in delaying the progression in relapsing-onset MS . Neurology 2007; 69: 1498 – 1507 .[Abstract/Free Full Text]
  • 71 Cadavid D Wolansky L Cook S Halper J Hill J Younes M . Betaseron versus copaxone in multiple sclerosis with triple-dose gadolinium and 3 Tesla MRI Endpoints (BECOME): announcement of secondary clinical outcomes. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 207.
  • 72 Polman CH O’Connor PW Havrdova E Hutchinson M Kappos L Miller DH . A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis . N Engl J Med 2006; 354: 899 – 910 .[Abstract/Free Full Text]
  • 73 Patti F Amato MP Caniatti L Di Monte E Ferrazza P Goretti B . Effects of two different doses of subcutaneous interferon beta-1a treatment on cognition in patients with early relapsing-remitting multiple sclerosis. Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 200.
  • 75 Mostert JP de Groot JC Ramsaransing GS Koch MW De Keyser J . Relationship between the extent of T2 lesions and the onset of secondary progression in multiple sclerosis . Eur J Neurol 2007; 14: 1210 – 1215 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 76 Río J Tintoré M Nos C Téllez N Galán I Pelayo R . Interferon beta in secondary progressive multiple sclerosis: daily clinical practice . J Neurol 2007; 254: 849 – 853 .[Medline] [Order article via Infotrieve]
  • 77 Ramo C Grau L . Clinical predictors of spontaneous benign multiple sclerosis. Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 701.
  • 78 Frederiksen J Nygaard M . Predictors of a benign course in multiple sclerosis. Programs and abstracts of the ECTRIMS 2007; 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Poster 702.
  • 79 Wu X Kuusisto H Dastidar P Huhtala H Nikkari ST Ukkonen M . Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels . Acta Neurol Scand. 2007; 116: 43 – 48 .[Medline] [Order article via Infotrieve]
  • 80 Scott LJ Figgitt DP . Mitoxantrone: a review of its use in multiple sclerosis . CNS Drugs. 2004; 18: 379 – 396 .[Medline] [Order article via Infotrieve]
  • 81 Buttinelli C Clemenzi A Borriello G Denaro F Pozzilli C Fieschi C . Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up . Eur J Neurol 2007; 14: 1281 – 1287 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 82 Hartung H Gonsett R Konig N Kwiecinski H Guseo A Morrissey H . Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized, multicentre trial . Lancet 2002; 360: 2018 – 2025 .[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
  • 83 Durelli L Ferrero B Ghezzi A Montanari E Zaffaroni M Bergui M . The Independent Comparison of Interferon (INCOMIN) Trial: a multicentre randomised trial comparing clinical and MRI efficacy of IFN beta-1a and beta-1b in multiple sclerosis. Annual meeting of the American Academy of Neurology; Philadelphia; April 2001. Neurology April 2001; 56 (Suppl. 3).
  • 84 Jeffery DR . Use of combination therapy with immunomodulators and immunosuppressants in treating multiple sclerosis . Neurology 2004; 63(suppl 6): S41 – S46 .[Abstract/Free Full Text]
  • 85 Rudick RA Stuart WH Calabresi PA Confavreux C Galetta SL Radue EW . Natalizumab plus interferon beta-1a for relapsing multiple sclerosis . N Engl J Med 2006; 354: 911 – 923 .[Abstract/Free Full Text]
  • 86 Casetta I Iuliano G Filippini G . Azathioprine for multiple sclerosis . Cochrane Database Syst Rev 2007; (4): CD003982 .
  • 87 Krishnan C Kaplin AI Brodsky RA Drachman DB Jones RJ Pham DL . Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis . Arch Neurol 2008; 65: 1044 – 1051 .[Abstract/Free Full Text]
  • 88 Gladstone DE Zamkoff KW Krupp L Peyster R Sibony P Christodoulou C . High-dose cyclophosphamide for moderate to severe refractory multiple sclerosis . Arch Neurol 2006; 63: 1388 – 1393 .[Abstract/Free Full Text]
  • 89 Fazekas F Lublin FD Li D Freedman MS Hartung HP Rieckmann P . Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial . Neurology 2008; 71: 265 – 271 .[Abstract/Free Full Text]
  • 91 Davies SL Moral MA . Spotlight on: clinical development of mycophenolate mofetil in multiple sclerosis . Drug News Perspect 2006; 19: 623 – 633 .
  • 92 Pawate S Wang L Sriram S Moses H . Mycophenolate mofetil in the treatment of multiple sclerosis. Presented at the 60th annual meeting of the American Academy of Neurology. Held in Chicago IL, April 13-20, 2008.
  • 94 Coles A . CAMMS 223 Study Group. Alemtuzumab compared with subcutaneous high-dose IFNB-1a in treatment-naive relapsing-remitting multiple sclerosis: primary efficacy outcomes of CAMMS223 at 3 years. Presented at the 60th annual meeting of the American Academy of Neurology. Held in Chicago, IL April 13-20, 2008. Scientific session.
  • http://www.pdl.com/index.cfm?navId=49
  • 96 Montalban X Wynn D Kaufman M Wang M Fong A . Preliminary CHOICE results: a phase 2, randomised, double-blind, placebo-controlled multicentre study of subcutaneous daclizumab in patients with active, relapsing forms of multiple sclerosis on interferon beta. Programs and abstracts of the ECTRIMS 2007: 23rd Congress of the European Committee for Treatment and Research in Multiple Sclerosis; October 11-14, 2007; Prague, Czech Republic. Abstract 50.
  • http://www.neurotodayonline.com/pt/re/neurotoday/fulltext.00132985-200805020-00009.html
  • 98 Hauser SL Waubant E Arnold DL Vollmer T Antel J Fox RJ . B-cell depletion with rituximab in relapsing-remitting multiple sclerosis . N Engl J Med 2008; 358: 676 – 688 .[Abstract/Free Full Text]
  • http://www.medicalnewstoday.com/printerfriendlynews.php?newsid=42811
  • 101 Goodin DS Frohman EM Hurwitz B O’Connor PW Oger JJ Reder AT . Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology . Neurology 2007; 68: 977 – 984 .[Abstract/Free Full Text]

Multiple Sclerosis, Vol. 15, No. 2 Suppl, S5-S35 (2009)
DOI: 10.1177/1352458508101134
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Free Full Text (Free PDF) Free
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Coyle, P
Right arrow Articles by Lublin, F
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Coyle, P
Right arrow Articles by Lublin, F
Right arrowPubmed/NCBI databases
Medline Plus Health Information
*Multiple Sclerosis
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Advertisement